Clinical Trial Update: Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) [Phase 3]

View source ↗

Summary

Phase 3 ACTIVATE trial evaluating tolvaptan in acute heart failure with high copeptin was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Samsca (tolvaptan) (tolvaptan)

Snippet

Sponsor: Maisel, Alan, M.D. | Conditions: Acute Heart Failure | Phase 3 | Status: WITHDRAWN